Camrelizumab plus chemotherapy as induction therapy followed by concurrent chemoradiotherapy and camrelizumab consolidation in limited-stage small cell lung cancer: a randomized phase II trial.
Di Liu, Letong Yang, Min Hu et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized phase II trial compared a camrelizumab-based induction and consolidation strategy with induction chemotherapy followed by concurrent chemoradiotherapy (CRT) alone in previously untreated patients with limited-stage small cell lung cancer. Among 41 enrolled patients, at median follow-up of 32.1 months, the 1-year progression-free survival rate was 65.5% with camrelizumab versus 47.4% with CRT alone (P = 0.029). Median progression-free survival was 24.0 months versus 11.8 months; median overall survival was not reached versus 23.9 months (P = 0.042). Severe immune-related adverse events were uncommon, and radiation pneumonitis rates were comparable.
Key findings
- The 1-year progression-free survival rate was 65.5% with camrelizumab versus 47.4% with CRT alone (P = 0.029).
- Median progression-free survival was 24.0 months versus 11.8 months; median overall survival was not reached versus 23.9 months (P = 0.042).
- Objective response rates were 100% with camrelizumab and 83.3% with CRT alone.
- Severe immune-related adverse events occurred in 4.8% of the camrelizumab group; radiation pneumonitis rates were comparable between groups.
Why it matters
Limited-stage small cell lung cancer has a need for effective strategies that improve disease control and survival. This trial reports better progression-free survival with camrelizumab added during induction and consolidation around CRT, alongside a manageable safety profile. The findings provide a rationale for further evaluation of this treatment sequence, while the phase II design and small enrolled population call for caution in interpreting the estimates.
What to keep in mind
The randomized phase II trial enrolled 41 patients, limiting the precision and generalisability of its survival estimates; the authors state that further validation is warranted.